Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster viewing 06

YO26 - Treatment of ALK positive metastatic adenocarcinoma lung - A case report of sequencing therapy.


03 Dec 2022


Poster viewing 06


Rajashree ashwath


R. ashwath1, A. Rauthan2, P. Patil3, K. Lahkar3, N.Y. Murthy3, P. VUNDEMODALU1, C. JOMI1, P. S N1, H. N.J1, A. Umashankar1

Author affiliations

  • 1 Medical Oncology, Manipal Comprehensive Cancer Center Manipal Hospital, 560017 - Bangalore/IN
  • 2 Medical Oncology Dept, Manipal Comprehensive Cancer Center Manipal Hospital, 560017 - Bangalore/IN
  • 3 Medical Oncology Department, Manipal Comprehensive Cancer Center Manipal Hospital, 560017 - Bangalore/IN


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract YO26

Case summary

Introduction - ALK rearrangement a distinct subset of non small cell lung cancer(NSCLC), incidence 2-7% highly sensitive, effectively treated with ALK TKI inhibitors. Different generations of ALK TKI increases the outcome of ALK positive lung cancer with sequencing the therapy with interim molecular testing for resistant mutation.

Methods - A 48 years male, never smoker presented in July 2017 with hemoptysis. PET CT - left hilar mass (2.4x1.3cm), bilateral lung nodules, lytic bone lesion with biopsy confirming adenocarcinoma. Diagnosed as adenocarcinoma lung with bone metastasis. Molecular testing (IHC) revealed EML4-ALK rearrangement. He was started on Alectinib 600mg twice daily with zoledronic acid from Aug 2017. He tolerated therapy with no side effects.

Results - Interim CT thorax (Dec 2017) showed partial response and Aug 2018 PET CT scan showed partial metabolic response. In Aug 2019, PET CT scan showed progressive hilar mass (3.2x2cm). He underwent re-biopsy confirming adenocarcinoma. NGS(Foundation One) report - EML4 -ALK G1202R mutation. Considering isolated progressive hilar mass he received SBRT and started on Lorlatinib 100mg daily (Sep 2019). Initial month he developed bilateral edema of legs, difficulty in walking and managed conservatively. Follow up PET CT scan (July 2021) showed complete metabolic response. He stopped therapy on his own from July 2021,he later developed significant loss of weight,hoarseness of voice with ECOG PS 3. In Dec 2021, PET CT scan showed progressive left hilar mass (2.2x1.6cm), increasing metabolic activity with bone lesions, he was restarted on Lorlatinib(Jan 2022) with X geva. PET CT scan (July 2022) - total resolution of hilar mass, bone lesions. Tolerated well with grade 2 hypertriglyceridemia, ECOG PS is 1. Hence our patient with a sequential approach have a durable ongoing OS of 5 years.

Conclusion - Presence of ALK gene predicts strong sensitivity to ALK inhibitors with excellent overall survival. Sequencing ALK inhibitor therapy has an impact on improving OS. Molecular testing and looking for ALK resistance mutation helps to choose Lorlatinib, the only sensitive TKI which targets (G1202R). This is an evolving precision based therapy, improves outcome in lung cancer.

Clinical trial identification

Editorial acknowledgement

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.